Genentech, Inc.
Phone: +16502251000
Fax: +1 (650) 225-6000
E-mail: https://www.gene.com/contact-us/email-us
| Type | Private ( Independent subsidiary) |
|---|---|
| Industry | Biotechnology |
| Founded | 1976 (1976) |
| Headquarters | South San Francisco, California, United States |
| Key people |
|
| Products | Avastin, Herceptin, Rituxan, Perjeta, Kadcyla, Gazyva, Tarceva, Ocrevus, Polivy, Tecentriq, Xofluza, Hemlibra, Venclexta, Esbriet, Cotellic, Alecensa, Zelboraf, Nutropin, Actemra, Lucentis, Xolair, Activase, Cathflo Activase, Xeloda, Boniva, TNKase, CellCept, Pegasys, Pulmozyme, Tamiflu, Valcyte, Anaprox, Cytovene, EC-Naprosyn, Erivedge, Fuzeon, Invirase, Klonopin, Kytril, Naprosyn, Rocephin, Roferon-A, Romazicon, Valium, Xenical, Zenapax |
| Revenue |  26.4 billion (2020) |
| Number of employees | 13,539 (July 2021) |
| Parent | Hoffmann-La Roche |
| Website | www.gene.com |
Genentech, Inc., is an American biotechnology corporation which became a subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.
As of July 2021, Genentech employed 13,539 people.
For detailed contact information visit location pages below.
Genentech, Inc.'s locations around the world
North America
Clinical Trials sponsored by Genentech, Inc.
-
Genentech, Inc.Recruiting
-
Genentech, Inc.RecruitingHepatocellular CarcinomaUnited States, Puerto Rico
-
Genentech, Inc.RecruitingRelapsed or Refractory Multiple MyelomaAustralia, Israel, South Korea
-
Genentech, Inc.RecruitingMelanoma | Cervical Cancer | HCC | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | NSCLC | Urothelial Carcinoma | HNSCC | Locally Advanced or Metastatic Solid Tumors | TNBC | Clear Cell RCCNetherlands, Spain, Taiwan, United States, Australia, Canada, Belgium, Sweden, Greece, South Korea
-
Genentech, Inc.CompletedDiabetic Macular EdemaUnited States, China, Puerto Rico
-
Genentech, Inc.Active, not recruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerUnited States, Spain, Japan, United Kingdom, Germany, Taiwan, Argentina, Italy, Singapore, Greece, South Africa, South Korea, Turkey (Türkiye)
-
Genentech, Inc.AvailableER+/HER2- Early or Locally Advanced/Metastatic Breast Cancer
-
Genentech, Inc.Active, not recruitingDiabetic Macular EdemaUnited States, Puerto Rico
-
Genentech, Inc.Active, not recruitingColorectal Cancer | Non-Small Cell Lung Cancer | Advanced Solid TumorsNew Zealand, Canada, Spain, Brazil, Belgium, Australia, United States, United Kingdom, Israel, Netherlands, Norway, Switzerland, Italy, Hungary, South Korea, Poland, Kenya
-
Genentech, Inc.Active, not recruitingDiabetic Macular EdemaUnited States, India, Puerto Rico, Kenya